Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi, Regeneron Begin Global Kevzara Clinical Trial Program In Patients With Severe Covid-19
Details : The US based trial will begin at medical centers in New York and will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo.
Product Name : Kevzara
Product Type : Antibody
Upfront Cash : Inapplicable
March 16, 2020
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kevzara at a dose of 200 mg or 400 mga in severely or critically illb patients hospitalized with COVID-19 did not meet its primary endpoint and key secondary endpointc when Kevzara was compared to placebo added to usual hospital care.
Product Name : Kevzara
Product Type : Antibody
Upfront Cash : Inapplicable
January 09, 2020
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sarilumab
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kevzara Approved for Active Polyarticular Juvenile Idiopathic Arthritis by FDA
Details : Kevzara (sarilumab), a IL-6R inhibitor has been approved bhy USFDA for patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis.
Product Name : Kevzara
Product Type : Antibody
Upfront Cash : Inapplicable
November 06, 2024
Lead Product(s) : Sarilumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sarilumab
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kevzara (sarilumab) binds to sIL-6R and mIL-6R and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 are involved in diverse physiological processes such as T-cell activation, stimulation of hematopoietic precursor cell prol...
Product Name : Kevzara
Product Type : Antibody
Upfront Cash : Inapplicable
February 28, 2023
Lead Product(s) : Sarilumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary analysis of the Phase 2 portion of the trial demonstrated that Kevzara rapidly lowered C-reactive protein (CRP), a key marker of inflammation, meeting the primary endpoint.
Product Name : Kevzara
Product Type : Antibody
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients
Details : U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).
Product Name : Kevzara
Product Type : Antibody
Upfront Cash : Inapplicable
February 07, 2020
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi and Regeneron Launch Second Kevzara Trial Against COVID-19
Details : The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
Product Name : Kevzara
Product Type : Antibody
Upfront Cash : Inapplicable
January 04, 2020
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
